Your browser doesn't support javascript.
loading
Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative.
Sanchez, Erlan; Wilkinson, Tim; Coughlan, Gillian; Mirza, Saira; Baril, Andrée-Ann; Ramirez, Joel; Binns, Malcolm A; Black, Sandra E; Borrie, Michael; Dilliott, Allison A; Dixon, Roger A; Dowlatshahi, Dar; Farhan, Sali; Finger, Elizabeth; Fischer, Corinne E; Frank, Andrew; Freedman, Morris; Goncalves, Rafaella A; Grimes, David A; Hassan, Ayman; Hegele, Robert A; Kumar, Sanjeev; Lang, Anthony E; Marras, Connie; McLaughlin, Paula M; Orange, Joseph B; Pasternak, Stephen H; Pollock, Bruce G; Rajji, Tarek K; Roberts, Angela C; Robinson, John F; Rogaeva, Ekaterina; Sahlas, Demetrios J; Saposnik, Gustavo; Strong, Michael J; Swartz, Richard H; Tang-Wai, David F; Tartaglia, Maria Carmela; Troyer, Angela K; Kvartsberg, Hlin; Zetterberg, Henrik; Munoz, Douglas P; Masellis, Mario.
Afiliação
  • Sanchez E; L.C. Campbell Cognitive Neurology Research Unit, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Wilkinson T; L.C. Campbell Cognitive Neurology Research Unit, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Coughlan G; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Mirza S; L.C. Campbell Cognitive Neurology Research Unit, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Baril AA; Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Ramirez J; Douglas Mental Health University Institute, McGill University, Montreal, Quebec, Canada.
  • Binns MA; Dr. Sandra Black Centre for Brain Resilience & Recovery, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Black SE; Rotman Research Institute, Baycrest Health Sciences, Toronto, Ontario, Canada.
  • Borrie M; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
  • Dilliott AA; Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Dixon RA; Dr. Sandra Black Centre for Brain Resilience & Recovery, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Dowlatshahi D; Lawson Health Research Institute, London, Ontario, Canada.
  • Farhan S; Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
  • Finger E; Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.
  • Fischer CE; Department of Psychology, Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada.
  • Frank A; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Freedman M; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Goncalves RA; Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.
  • Grimes DA; Lawson Health Research Institute, London, Ontario, Canada.
  • Hassan A; Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
  • Hegele RA; Keenan Research Centre for Biomedical Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.
  • Kumar S; Bruyere Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
  • Lang AE; Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Marras C; Rotman Research Institute, Baycrest Health Sciences, Toronto, Ontario, Canada.
  • McLaughlin PM; Department of Medicine, Mt. Sinai Hospital, Toronto, Ontario, Canada.
  • Orange JB; Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada.
  • Pasternak SH; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Pollock BG; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Rajji TK; Brain and Mind Research Institute, Ottawa, Ontario, Canada.
  • Roberts AC; Thunder Bay Regional Research Institute, Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada.
  • Robinson JF; Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
  • Rogaeva E; Robarts Research Institute, Western University, London, Ontario, Canada.
  • Sahlas DJ; Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Saposnik G; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
  • Strong MJ; Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Swartz RH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada.
  • Tang-Wai DF; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada.
  • Tartaglia MC; Nova Scotia Health, Halifax, Nova Scotia, Canada.
  • Troyer AK; Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Kvartsberg H; School of Communication Sciences and Disorders, Western University, London, Ontario, Canada.
  • Zetterberg H; Canadian Centre for Activity and Aging, Western University, London, Ontario, Canada.
  • Munoz DP; Department of Clinical Neurological Sciences, Robarts Research Institute, Western University, London, Ontario, Canada.
  • Masellis M; Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Alzheimers Dement ; 20(3): 1753-1770, 2024 03.
Article em En | MEDLINE | ID: mdl-38105605
ABSTRACT

INTRODUCTION:

We investigated whether novel plasma biomarkers are associated with cognition, cognitive decline, and functional independence in activities of daily living across and within neurodegenerative diseases.

METHODS:

Glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), phosphorylated tau (p-tau)181 and amyloid beta (Aß)42/40 were measured using ultra-sensitive Simoa immunoassays in 44 healthy controls and 480 participants diagnosed with Alzheimer's disease/mild cognitive impairment (AD/MCI), Parkinson's disease (PD), frontotemporal dementia (FTD) spectrum disorders, or cerebrovascular disease (CVD).

RESULTS:

GFAP, NfL, and/or p-tau181 were elevated among all diseases compared to controls, and were broadly associated with worse baseline cognitive performance, greater cognitive decline, and/or lower functional independence. While GFAP, NfL, and p-tau181 were highly predictive across diseases, p-tau181 was more specific to the AD/MCI cohort. Sparse associations were found in the FTD and CVD cohorts and for Aß42/40 .

DISCUSSION:

GFAP, NfL, and p-tau181 are valuable predictors of cognition and function across common neurodegenerative diseases, and may be useful in specialized clinics and clinical trials.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Doenças Neurodegenerativas / Demência Frontotemporal / Doença de Alzheimer / Disfunção Cognitiva Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Alzheimers Dement Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Doenças Neurodegenerativas / Demência Frontotemporal / Doença de Alzheimer / Disfunção Cognitiva Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Alzheimers Dement Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá